HKSE · 1177.HK
Sino Biopharmaceutical Limited
HK$4.82-HK$0.03 (-0.62%)
Sino Biopharmaceutical Limited’s quoted price sits in the lower half of its reported 52-week range, 35.56% below the high.
Loading market information…
HKSE · 0512.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:41 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Grand Pharmaceutical Group Limited’s quoted price sits in the lower half of its reported 52-week range, 51.35% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Grand Pharmaceutical Group Limited’s forward annual dividend is HK$0.17 per share, paid annual. The forward yield is 3.91% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Grand Pharmaceutical Group Limited’s next earnings report is currently expected on Mar 17, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Grand Pharmaceutical Group Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products. In addition, the company provides bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. The company has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company has a business collaboration with the Sirtex Group agreement to enable collaboration on research and development of pharmaceutical products. The company has a strategic partnership with the University of Hong Kong for the research and development of drugs in the field of anti-infection and the industrialization of the research results. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited. The company was incorporated in 1995 and is based in Central, Hong Kong.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Mar 22, 2023 |
| HK$0.39 |
| HK$4.35B-60.46% vs estimate |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$4.82-HK$0.03 (-0.62%)
Sino Biopharmaceutical Limited’s quoted price sits in the lower half of its reported 52-week range, 35.56% below the high.
HK$4.63+HK$0.13 (+2.89%)
China Resources Pharmaceutical Group Ltd.’s quoted price sits in the lower half of its reported 52-week range, 29.17% below the high.
HK$10.15-HK$0.23 (-2.22%)
Simcere Pharmaceutical Group Limited’s quoted price sits in the lower half of its reported 52-week range, 29.49% below the high.
HK$9.83-HK$0.08 (-0.81%)
China Medical System Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 36.63% below the high.
HK$6.87+HK$0.01 (+0.15%)
The United Laboratories International Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
HK$15.31+HK$0.17 (+1.12%)
Consun Pharmaceutical Group Limited’s quoted price sits in the lower half of its reported 52-week range, 21.45% below the high.
HK$2.59+HK$0.01 (+0.39%)
SSY Group Limited’s quoted price sits in the lower half of its reported 52-week range, 18.71% below the high.
HK$0.73+HK$0.02 (+2.11%)
Sihuan Pharmaceutical Holdings Group Ltd.’s quoted price sits in the lower half of its reported 52-week range, 59.5% below the high.
